SEC Company Response from Ayala Pharmaceuticals, Inc. (CIK 0001797336) — May 5, 2020
Ayala Pharmaceuticals, Inc. (CIK 0001797336)
Date: May 5, 2020 · CIK: 0001797336 · Accession: 0001193125-20-133705
AI Filing Summary & Sentiment
File numbers found in text: 333-236942
Letter
Via EDGAR Transmission United States Securities and Exchange Commission Office of Healthcare and Insurance Attention: Courtney L. Lindsay II Ayala Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed March 6, 2020 Registration No. 333-236942
Dear Mr. Lindsay:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on May 7, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Ayala Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff.
Please contact Keith L. Halverstam of Latham & Watkins LLP, counsel to the Company, at (212) 906-1761, or in his absence, Peter N. Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Sincerely yours,
Ayala Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP May 5, 2020 Via EDGAR Transmission United States Securities and Exchange Commission Office of Healthcare and Insurance 100 F Street, N.E. Mail Stop 4720 Washington, D.C. 20549 Attention: Courtney L. Lindsay II Re: Ayala Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed March 6, 2020 Registration No. 333-236942 Dear Mr. Lindsay: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on May 7, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Ayala Therapeutics, Inc. (the “Company”) or its counsel may request via telephone call to the staff. Please contact Keith L. Halverstam of Latham & Watkins LLP, counsel to the Company, at (212) 906-1761, or in his absence, Peter N. Handrinos at (617) 948-6060, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter. Sincerely yours, Ayala Pharmaceuticals, Inc. By: /s/ Roni Mamluk Roni Mamluk Chief Executive Officer cc: Keith L. Halverstam, Esq. Peter N. Handrinos, Esq.